Please login to the form below

Not currently logged in
Email:
Password:

Prostate cancer deaths double in men with faulty gene

Rencently published findings show that men with prostate cancer caused by a faulty BRCA2 gene are twice as likely to die from the disease as men with a faulty BRCA1 gene

Cancer Research UK has published findings which show that men with prostate cancer caused by a faulty BRCA2 gene are twice as likely to die from the disease as men with a faulty BRCA1 gene.

Prostate cancer takes the lives of around 10,000 men in the UK each year. With around 35,000 new cases diagnosed each year, and a one in 14 lifetime risk of developing it, prostate cancer is the most common cancer in men in the UK.

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "Although only a very small percentage of men with prostate cancer will carry a faulty BRCA2 gene, they're much more likely to die from the disease. It's important that more research is done in this area to ensure that this group is targeted effectively so cancer is picked up at an early stage and, more importantly, that they are given the most appropriate treatment."

Results from previous studies have shown that men with a faulty BRCA2 gene can be up to five times more likely than the general population to develop prostate cancer. Dr Steven Narod, the lead researcher, said that the new findings are important, as men with a faulty BRCA2 gene are not responding well to current treatments.

25th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics